text_1: The treatment of cancer patients with co-IR blockade does not cause any adverse autoimmune events.
text_2: The emergence of immuno-oncology as the first broadly successful strategy for metastatic cancer will require clinicians to integrate this new pillar of medicine with chemotherapy, radiation, and targeted small-molecule compounds.